Premium
Cell proliferation in childhood acute leukemia. Comparison of Ki‐67 and proliferating cell nuclear antigen immunocytochemical and DNA flow cytometric analysis
Author(s) -
Ito Man,
Tsurusawa Masahito,
Zha Zhimin,
Kawai Susumu,
Takasaki Yoshinari,
Fujimoto Takeo
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920415)69:8<2176::aid-cncr2820690827>3.0.co;2-7
Subject(s) - proliferating cell nuclear antigen , acute leukemia , leukemia , medicine , antigen , flow cytometry , bone marrow , pathology , ki 67 , monoclonal antibody , microbiology and biotechnology , immunology , antibody , biology , immunohistochemistry
Abstract The proliferative activity of bone marrow leukemia cells was determined by DNA flow cytometric (FCM) analysis and labeling index (LI) of Ki‐67 monoclonal antibodies and proliferating cell nuclear antigen (PCNA) autoantibodies in 73 children with acute leukemia. LI of Ki‐67 varied greatly from patient to patient (range, 0.4% to 42.2%; mean, 18.8%) and differed significantly between acute lymphoblastic leukemia (ALL) and acute nonlymphoblastic leukemia (ANLL). In ALL, the Ki‐67 LI showed a positive correlation with the S‐phase fraction (SPF) determined by DNA FCM analysis, whereas, in ANLL, there was a discrepancy between the Ki‐67 LI and SPF. In contrast, LI of PCNA varied less among the patients (range, 57.2% to 100%; mean, 90.3%), and the value was always higher than that of the Ki‐67 L1 in individual patients. A significant relationship between PCNA LI and the percentage of blast cells was found in peripheral blood leukocytes from patients with leukemia. These results suggest that the Ki‐67 LI reflects differences in the proliferative activity depending on the subtype of the disease and that the PCNA LI is useful as a marker of proliferating cells.